Cargando…

Correction to: MicroRNA-21 guide and passenger strand regulation of adenylosuccinate lyase-mediated purine metabolism promotes transition to an EGFR-TKI-tolerant persister state

Detalles Bibliográficos
Autores principales:	Zhang, Wen Cai, Skiados, Nicholas, Aftab, Fareesa, Moreno, Cerena, Silva, Luis, Corbilla, Paul Joshua Anthony, Asara, John M., Hata, Aaron N., Slack, Frank J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750856/ https://www.ncbi.nlm.nih.gov/pubmed/36002769 http://dx.doi.org/10.1038/s41417-022-00523-9

Ejemplares similares

MicroRNA-21 guide and passenger strand regulation of adenylosuccinate lyase-mediated purine metabolism promotes transition to an EGFR-TKI-tolerant persister state
por: Zhang, Wen Cai, et al.
Publicado: (2022)

Adenylosuccinate lyase deficiency
por: Jurecka, Agnieszka, et al.
Publicado: (2014)

MRI findings of hypomyelination in adenylosuccinate lyase deficiency
por: Kayfan, Samar, et al.
Publicado: (2018)

Molecular comparison of Neanderthal and Modern Human adenylosuccinate lyase
por: Van Laer, Bart, et al.
Publicado: (2018)

Clinical and molecular characterization of patients with adenylosuccinate lyase deficiency
por: Mastrogiorgio, Gerarda, et al.
Publicado: (2021)

Prevalence of adenylosuccinate lyase deficiency based on aggregated exome data
por: Ferreira, Carlos R.
Publicado: (2017)

A mathematical model for the adenylosuccinate synthetase reaction involved in purine biosynthesis
por: Oshchepkova-Nedosekina, Evgeniya A, et al.
Publicado: (2007)

Diagnosis of adenylosuccinate lyase deficiency by metabolomic profiling in plasma reveals a phenotypic spectrum
por: Donti, Taraka R., et al.
Publicado: (2016)

Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer
por: Zurlo, Giada, et al.
Publicado: (2019)

Adenylosuccinate lyase deficiency affects neurobehavior via perturbations to tyramine signaling in Caenorhabditis elegans
por: Moro, Corinna A., et al.
Publicado: (2023)

Very mild isolated intellectual disability caused by adenylosuccinate lyase deficiency: a new phenotype()
por: Macchiaiolo, Marina, et al.
Publicado: (2020)

Broadening phenotype of adenylosuccinate lyase deficiency: A novel clinical pattern resembling neuronal ceroid lipofuscinosis
por: Mastrangelo, Mario, et al.
Publicado: (2019)

Novel mutations in ADSL for Adenylosuccinate Lyase Deficiency identified by the combination of Trio-WES and constantly updated guidelines
por: Mao, Xiao, et al.
Publicado: (2017)

Carcinogenic effect of adenylosuccinate lyase (ADSL) in prostate cancer development and progression through the cell cycle pathway
por: Liao, Jinling, et al.
Publicado: (2021)

A comprehensive method for determining cellular uptake of purine nucleoside phosphorylase and adenylosuccinate synthetase inhibitors by H. pylori
por: Wojtyś, Marta Ilona, et al.
Publicado: (2021)

A mild form of adenylosuccinate lyase deficiency in absence of typical brain MRI features diagnosed by whole exome sequencing
por: Macchiaiolo, Marina, et al.
Publicado: (2017)

Child with adenylosuccinate lyase deficiency caused by a novel complex heterozygous mutation in the ADSL gene: A case report
por: Wang, Xing-Chen, et al.
Publicado: (2022)

Investigating Immunization With Nucleotide Enzymes of Schistosoma mansoni: Nucleoside Diphosphate Kinase and Adenylosuccinate Lyase as New Antigenic Targets Against Schistosomiasis
por: Cagnazzo, Túlio di Orlando, et al.
Publicado: (2020)

Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis
por: Taha-Mehlitz, Stephanie, et al.
Publicado: (2021)

OR05-02 Silencing Of Adenylosuccinate Lyase Impairs Growth And Perturbs Mitochondrial Function Of Endocrine Therapy Resistant Breast Cancer Cells
por: Yadav, Anil K, et al.
Publicado: (2023)

Structure of Staphylococcus aureus adenylosuccinate lyase (PurB) and assessment of its potential as a target for structure-based inhibitor discovery
por: Fyfe, Paul K., et al.
Publicado: (2010)

Adenylosuccinic Acid: An Orphan Drug with Untapped Potential
por: Rybalka, Emma, et al.
Publicado: (2023)

An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1
por: Aftab, Fareesa, et al.
Publicado: (2023)

Homology Modelling and Molecular Docking Studies of Selected Substituted Benzo[d]imidazol-1-yl)methyl)benzimidamide Scaffolds on Plasmodium falciparum Adenylosuccinate Lyase Receptor
por: Oduselu, Gbolahan O, et al.
Publicado: (2019)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
por: Yu, Jiang-Yong, et al.
Publicado: (2016)

Adenylosuccinic acid therapy ameliorates murine Duchenne Muscular Dystrophy
por: Timpani, Cara A., et al.
Publicado: (2020)

Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
por: LI, JING, et al.
Publicado: (2013)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

The Significance of MMP-1 in EGFR-TKI–Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting
por: Saito, Ryoko, et al.
Publicado: (2018)

Adenylosuccinic Acid Is a Non-Toxic Small Molecule In Vitro and In Vivo
por: Timpani, Cara A., et al.
Publicado: (2023)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
por: Xia, Guo-Hao, et al.
Publicado: (2014)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
por: Cao, Peijun, et al.
Publicado: (2022)

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
por: Arasada, Rajeswara Rao, et al.
Publicado: (2018)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

EGFR-TKI不良反应管理专家共识
Publicado: (2019)

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
por: Zhao, Lihao, et al.
Publicado: (2019)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan, Jiadi, et al.
Publicado: (2021)

Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients
por: Chen, Yi, et al.
Publicado: (2023)

Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study
por: Yang, Wenjing, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_au44v35gbf5fb0dklhfsbig9u9